Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $548.05 +1.44%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Vertex Pharma reaffirms FY2023 revenue of $9.55-9.7 billion, versus the consensus of $9.7 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
